Robert Zupko | Center for Infectious Disease Dynamics
Despite the progress of the past twenty years, Plasmodium falciparum malaria continues to be a major public health concern with about 241 million cases and 627,000 deaths in 2020. One means of combating malaria has been through the use of artemisinin-based combination therapies (ACTs), which have been instrumental in preventing deaths and reducing transmission. However, the recent appearance of artemisinin resistant P. falciparum in Africa suggests that innovative approaches are needed to prolong the efficacy of ACTs while next generation therapies are developed.